Vivesto (VIVE) Q1 2025 earnings summary

Executive summary

• Advanced key development projects and achieved significant regulatory milestones in Q1 2025, including strategic licensing and acquisition agreements.

• Secured a regional license deal for Apealea in China, Hong Kong, Macao, and Taiwan with Zhida Pharma, including upfront and milestone payments up to $5.85 million and future royalties.

• Expanded veterinary oncology program with new clinical studies in dogs and cats, and acquired full global rights to Cantrixil, eliminating future milestone and royalty obligations.

• Continued cost reduction efforts, lowering annual cost base by over SEK 35 million, and secured a SEK 10 million credit facility from the main shareholder.

Financial highlights

• Net sales were SEK 0 thousand (0) for Q1 2025.

• Operating result was SEK -8,588 thousand (-9,179) compared to the same quarter last year.

• Net result after tax was SEK -8,288 thousand (-8,421) year-over-year.

• Earnings per share before and after dilution were SEK -0.02 (-0.02) year-over-year.

• Cash and short-term investments totaled SEK 23,562 thousand (60,414) at period end.

Outlook and guidance

• Cash position, including the new credit facility, is expected to fund operations into 2026.

• Management continues to evaluate financing options, including partnerships and capital markets, to secure long-term operations.

• Several key milestones are targeted for the remainder of 2025, including interim results from the Paccal Vet dog study.